Dabogratinib (ACH)
Achondroplasia / Skeletal Dysplasia
Key Facts
About Tyra Biosciences
Tyra Biosciences is a clinical-stage biotech focused on developing next-generation, selective FGFR inhibitors for oncology and genetically defined skeletal conditions. Its core value proposition is its proprietary SNÅP discovery platform, which enables rapid, structure-based drug design to tackle resistance mutations and improve selectivity. The company has built a robust pipeline led by oral dabogratinib, now in Phase 2 for achondroplasia and with IND clearance for bladder cancer, supported by a strong team with deep drug development and commercialization expertise.
View full company profile